Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Petrylak D. P. , de Wit R., Chi K. N. , Drakaki A., Sternberg C. N. , Nishiyama H., ...Daha Fazla

LANCET ONCOLOGY, cilt.21, ss.105-120, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 21 Konu: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/s1470-2045(19)30668-0
  • Sayfa Sayıları: ss.105-120


Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial.